Programme

Our detailed interactive programme will be available here very soon.

All times are in Central European Summer Time (CEST).



 
 
Tuesday 19 October 2021
14:00-16:30





 
Plenary session 1: 2021 Opening session




Chairs: Hildegard Büning, Hannover Medical School 
Thierry VandenDriessche, VUB

Hildegard Büning: Welcome 
 Thierry VandenDriessche: Opening words
INV02: Ugur SahinBioNTech, Mainz
INV03: Mark Kay, Stanford University
INV04: Drew Weissman, University of Pennsylvania
Nucleoside-Modified mRNA-LNP Therapeutics
 
16:30-17:00  
17:00-19:00 Session 1a: CNS & Sensory I
 
Chairs: 

INV05: María José de Castro LópezHospital Clínico Universitario de Santiago de Compostela
Updated Results of Transpher A, a Multicenter, Single-Dose, Phase 1/2 Clinical Trial of ABO-102 Gene Therapy for Sanfilippo Syndrome Type A (Mucopolysaccharidosis IIIA)
INV06: Manny Simmons, Akouos, Boston MA
Inner Ear Conditions: Development of Precision Genetic Medicines in a New Therapeutic Area
INV07: Eri Hashino, Indiana University School of Medicine, Indianapolis

OR01:
OR02:
Session 1b: AAV as a gene therapy tool
from virus to vector


In memoriam - Mavis Agbandje-Mckenna

Chairs:


INV08: Dirk Grimm, Heidelberg University
INV09: Hildegard Büning, Hannover Medical School
INV10: Guangping Gao, University of Massachusetts
INV11: Aravind Asokan, Duke University School of Medicine, NC
Engineering AAV Biology
 
Session 1c: CAR T & CAR NK cells


Chairs: Hinrich Abken, Universitätsklinikum Regensburg
Dirk Nettlebeck, DKFZ, Heidelberg

INV12: Michael Hudecek, 
Universitätsklinikum Würzburg
INV13: Winfried Wels, Georg Speyer Haus, Frankfurt
CAR-engineered NK cells as allogeneic off-the-shelf therapeutics

OR03:
OR04:
OR05:
OR06:
19:30-20:30  
Sponsor symposium
19:30-20:30
 
 
Wednesday 20 October 2021
09:00-11:00 Session 2a: Primary immunodeficiencies 



Chairs:

INV14: Elena Almarza, Rocket Pharma, Madrid
Gene Therapy for Leukocyte Adhesion Deficiency Type I (LAD-I): A 12-year roadmap
INV15: Karin Pike Overzet, Leiden University
Bringing lentiviral gene therapy to clinical application for RAG1-SCID
INV16: GIorgia Santilli, Ucl, London
Genome editing in human hematopoietic stem cells for the treatment of X-linked agammaglobulinemia

OR07:
OR08: 
 
Session 2b: Gene targeting



Chairs: Adi Barzel, Tel Aviv University
Ayal Hendel, Bar- Ilan University, Tel Aviv

INV17: Jacob Corn, ETH Zurich
Hematopoietic stem cell re-quiescence balances stemness and HDR during genome editing
INV18: Adi Barzel, Tel Aviv University

OR09:
OR10:

OR11:
OR12: 
Session 2c: Immunotherapy for cancer



Chairs:

INV19: Sonia Guedan, Idibaps, Barcelona
INV20: Bart Neyns, UZ Brussels
Exploring the potential of dendritic cell therapy for the treatment of advanced melanoma, from moDC to myDC
OR13: 
OR14:
OR15:
OR16:
11:00-11:30  
11:30-13:30
 
Plenary session 2: Advances in preclinical studies

Chairs: 

INV21: Luigi Naldini, SR Tiget, Milan
INV22: Gloria Gonzalez Aseguinolaza, University of Navarra, Pamplona
INV23: Alessia Cavazza, Institute of Child Health, UCLondon
Preclinical studies for a hematopoietic stem cell gene editing platform to treat Wiskott-Aldrich Syndrome.
INV24: Len Seymour, Oxford University
Using oncolytic viruses to mediate HLA-independent immunotherapy
 
13:30-15:15   Sponsor symposium
13:45-14:45

Sponsor symposium
13:45-14:45


 
15:15-17:15 Session 3a:  Liver & metabolic



Chairs: 

INV25: Alberto Auricchio, Tigem, Naples
AAV-mediated liver gene therapy for mucopolysaccharidosis VI
INV26: Charles Venditti, NIH, NHGRI, Bethesda, MD

OR17:
OR18:
OR19:
OR20:

 
Session 3b: Cardiovascular & lung diseases
 

Chairs:

INV27: John Engelhardt, University of Iowa
INV28: Silva Priori, University of Pavia 
Gene Therapy to the heart: challenges and progresses
INV29: Seppo Ylä-Herttuala, Univeristy of Eastern Finland, Kuppio
Cardiac gene therapy with VEGF-B

OR21:
OR22: 
Session 3c: Muscle diseases




Chairs:

INV30: Charles Gersbach, Duke University School of Medicine, NC
Genome Editing for The Treatment of Duchenne Muscular Dystrophy
INV31: Isabelle Richard, Genethon, Evry
Gene replacement therapy in LGMD-R1
INV32: Perry Shieh, UCLA
ASPIRO gene therapy trial in X-linked myotubular myopathy (XLMTM): update on preliminary efficacy and safety findings

OR23: 

OR24: 

17:15-17:45  
17:45-19:45 Plenary session 3: Gene therapy trials




Chairs: 

INV33: Alessandra Biffi, University of Padova, Harvard Stem Cell Institute
Innovative HSC gene therapy approaches for neurodegenerative diseases
INV34: Chiara Bonini, Ospedale San Raffaele, Milan
Genome editing for cancer immunotherapy
INV35: Selim Corbacioglu, University Hospital Regensburg
INV36: Jose Alain Sahel, Institut de la vision, Paris
 
Thursday 21 October 2021
09:00-11:00

 
Session 4a: CNS & sensory II

Chairs: 

INV37: Nathalie Cartier, Institut de la Moelle et du Cerveau, Paris
INV38: Jane Hughes, Gyroscope Therapeutics Limited, Stevenage
INV39: Deniz Dalkara, Institut de la vision, Paris
Early to late stage gene therapy interventions for inherited retinal degenerations

OR25: 

OR26: 

 
Session 4b:Gene editing I



Chairs:

INV40: Anna Villa, SR Tiget, Milan
INV41: Manuel Gonçalves, Leiden University Medical Center
Expanding genome-editing tool delivery and targeting range in human cells

OR27: 

OR28:
OR29:
OR30 

 
Session 4c: Hematopoietic & bleeding disorders I

Chairs: 

INV42: Wolfgang Miesbach, Goethe University Hospital, Frankfurt
Current update of clinical trials on gene therapy for haemophilia
INV43: Alessio Cantore, SR Tiget, Milan
Lentiviral gene therapy to the liver for hemophilia and beyond

OR31: 

OR32:
OR33:
OR34 

10:30-11:00  
11:00-13:45

 
Plenary session 4: Presidential symposium


Chairs: Hildegard Büning, Juan Bueren

INV44: Hildegard Büning, Hannover Medical School
Presidential address

INV45: Hans Clevers, Utrecht University

INV46: Alessandro Aiuti, SR Tiget, Milan 
Else Kröner Fresenius Award



INV47: ESGCT Outstanding achievement award 



OR35: ESGCT Young Investigator award

 
13:45-15:15   Sponsor symposium
13:45-14:45


 
Sponsor symposium
15:15-17:15 Session 5a: Non coding RNA

Chairs: 

INV48:  Stefanie Dimmeler, Goethe-University Frankfurt
INV49: Sandro Banfi, Tigem, Naples
INV50

OR36: 
OR37: 

 
Session 5b: Gene editing II



Chairs:

INV51: Els Verhoeyen, University of Nice, ENS Lyon
INV52: Rodolfo Murillas, Ciemat, Madrid
Genome editing strategies for genodermatoses therapy

OR38:
OR39:
OR40:
OR41:
Session 5c: Gene therapy: A bridge
to fight infectious diseases


Chairs: Mike McCune, Bill & Melinda Gates Foundation

INV53: Frank Buchholz,TU Dresden
Development of Designer-Recombinases to target retroviral infections
INV54: Luk Vandenberghe,
Harvard Medical School, MA
INV55: Scott Kitchen, UCLA
Engineering CAR-T cells and Cell-Based Vaccines against HIV

OR42: 
OR43: 
 
17:15-17:45  
17:45-19:45

 
Plenary session 5: Covid-19 & the risk of future zoonosis

Chairs: 

INV56: Shi Zhengli, Wuhan Institute of Virology
INV57: 
INV58: 
INV59: 
 
Friday 22 October 2021
09:00-11:00

 
Session 6a: Oncolytic viruses

Chairs: 

INV60: Tomoki Todo, The University of Tokyo
INV61: Victor Van Beusechem, Amsterdam UMC
Next-generation oncolytic adenoviruses: preclinical and early clinical evaluation

OR44: 
OR45: 
OR46: 
OR47: 
 
Session 6b: Stem cells & regenerative medicine
Chairs: 

INV62: Maurillio Sampaolesi, KU Leuven
INV63: Cesar Nombela-Arrieta, University Hospital Zurich

OR48: 
OR49:
OR50:
OR51: 
Session 6c: Manufacturing

Chairs: 

INV64: Eduard Ayuso, Dinaqor, Pfäffikon 
INV65: Stephen Howe, GSK, Stevenage
Manufacturing process development to industrialise ex vivo gene therapy

OR52: 
OR53: 
11:00-11:30  
11:30-13:30 Session 7a: Safety

Chairs: 

INV66: Axel Schambach, Hannover Medical School
INV67: Ian Alexander, The University of Sydney
AAV vector safety considerations in liver-targeted gene therapy

OR54: 
OR55: 
OR56:
OR57:


 
Session 7b: Patient perspective & regulatory
Chairs: 

INV68:
INV69:
INV70:
INV71:

 
Session 7c: Late breaking abstracts

Chairs: 

 
13:30-14:30      
14:30-16:30
Session 8a: Hematopoietic & bleeding disorders II
Chairs: 

INV72: David Williams, Harvard Medical School, MA
Clinical Application of Post-transcriptional Silencing of BCL11A.
INV73: Marina Cavazzana, Institut Imagine, Hôpital Necker, Paris
Gene Therapy in Genetic Disorders.
 INV74:

OR58: 
OR59: 
 
Session 8b: AAV immunology

Chairs: 

INV75: Ying Kai Chan, Harvard University
New Applications, New Immunological Challenges
INV76: Giuseppe Ronzetti, Genethon, Evry


OR60
OR61
OR62
OR63

 
Session 8c: ASGCT

Chairs: 

INV77:
INV78:
INV79:
INV80:
16:30-17:00  
17:00-19:00 Plenary session 6: Gene editing




Chairs: 

INV81: Dan Bauer, Harvard University
INV82: Julian Grunewald, Massachusetts General Hospital
Engineering reduced size CRISPR prime editor proteins that retain efficient activities in human cells
INV83: Toni Cathomen, University of Freiburg
Assessing and mitigating off-target effects in therapeutic genome editing.
INV84: Sam Sternberg, Columbia University, NYC
Targeted DNA integration without double-strand breaks using CRISPR RNA-guided transposons

Closing remarks
 

OUR SPONSORS

DIAMOND

European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor

PLATINUM

European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor

GOLD

European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor

SILVER

European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor

BRONZE

European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor European Society for Gene and Cell Therapy Sponsor

SUPPORTER